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The glycoprotein IIb/IIIa antagonist 
c7E3 inhibits platelet aggregation in the 
presence of heparin-associated antibodies 
Timothy K. Liem, MD, Rosemary Teel, MT,  Shivendra Shukla, PhD, and 
Donald Silver, MD, Columbia, Mo. 
Purpose: Heparin-associated antibodies (HAAb), in the presence of heparin, can cause 
platelet activation and aggregation. The purpose of this study was to assess whether a 
platelet glycoprotein (GP) I Ib/ I I Ia receptor antagonist, c7E3, would inhibit platelet 
aggregation i  the presence of HAAb. If aggregation is inhibited by c7E3, enzyme-linked 
immunosorbent assays (ELISA) would be done to determine whether c7E3 interfered 
with the binding of heparin and the HAAb. 
Methods: HAAb-positive plasmas from 21 patients (determined by platelet aggregation 
assays) were studied. Normal donor platelet-rich plasmas (PRP) were incubated (1 
minute) with either saline solution or 3 ~g/ml of c7E3. Platelet-poor plasma from 
patients with HAAb and one of three sources of heparin (25 ~1, 10 U/ml; porcine 
heparin, bovine heparin, and low molecular weight heparin [enoxaparin]) were added to 
the PRP mixture. Aggregation was determined using a platelet aggregometer bymeasur- 
ing time to aggregation, the slope of the aggregation curve, and the percent change in 
optical density. 
Results: Platelet aggregation occured in 100%, 100%, and 95% of the saline solution 
incubations exposed to porcine heparin, bovine heparin, and enoxaparin, respectively. 
Incubation with c7E3 caused 100% inhibition of platelet aggregation i plasma exposed 
to porcine heparin, bovine heparin, and enoxaparin. The optical density curves obtained 
from the ELISA, which were dependent on the binding of HAAb to heparin, were not 
significantly different when c7E3 was compared to buffer alone. 
Conclusions: The GP I Ib/ I I Ia receptor antagonist, c7E3, inhibits HAAb-induced platelet 
aggregation via a mechanism that does not appear to interfere with the binding between 
heparin and HAAb. Clinical trials are warranted to assess whether GP IIb/I I Ia antagonists 
may allow patients with HAAb to safely receive h parin. (J Vasc Surg 1997;25:124-30.) 
Heparin-induced thrombocytopenia (HIT) oc- 
curs as a complication in 5% to 6% of patients who 
receive heparin therapy. 1,2 As many as 61% of pa- 
tients with HIT  develop arterial or venous throm- 
botic complications related to platelet activation and 
aggregation. 3 To date, the only completely effective 
treatment for H IT  is cessation of heparin therapy. 
Attempts to treat H IT  with platelet function-inhib- 
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iting agents such as aspirin, dipyridamole, and ilo- 
prost have met with variable success. 
Recently, the central role of the platelet glycopro- 
tein I Ib/ I I Ia  (GP I Ib/ I I Ia)  receptor in mediating 
platelet aggregation has been elucidated. Binding of 
the GP I Ib / I I Ia  receptor to fibrinogen and other 
adhesive glycoproteins (yon Willebrand factor, vitro- 
nectin, and fibronectin) is one of the last steps in the 
pathway leading to platelet aggregation, regardless of 
the platelet agonist. 4 
Agents have been developed that bind to the GP 
I Ib / I I Ia  receptor on human platelets and effectively 
inhibit aggregation. 4 The Fab (fragment antigen 
binding) fragment of a chimeric murine monoclonal 
antibody (c7E3) that binds to the GP I Ib / I I Ia  re- 
ceptor has undergone xtensive valuation in clinical 
trials. The purpose of this study was to determine 
whether the c7E3 Fab fragment could inhibit plate- 
let aggregation i the presence of heparin and hepa- 
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fin-associated antibodies (HAAb), and whether the 
c7E3 interfered with the binding of heparin to the 
HAAb. 
METHODS 
The study was approved by the Institutional Re- 
view Board at the University of Missouri-Columbia. 
Plasma from 21 patients with known HAAb, as de- 
termined by platelet aggregation testing and patient 
clinical course, was obtained from the Thromboem- 
bolic Laboratory at the University of Missouri-Co- 
lumbia. Platelet-rich plasma from normal donors and 
platelet-poor plasma from affected patients were pre- 
pared by differential centrifugation of whole blood 
collected in a 3.8% citrate solution. 
The platelet-fich plasmas (0.1 ml) were incu- 
bated with either 10 ~1 (3 ~g/ml) of the c7E3 Fab 
fragment (Abciximab, Eli Lilly and Co., Indianapo- 
lis) or 10 I~1 of normal saline for I minute at room 
temperature. Platelet-poor plasmas (0.15 ml) from 
patients with HAAb were then added and the mix- 
tures incubated for 3 minutes at 37 ° C. Each mixture 
was then incubated in an aggregometer with one of 
three sources of heparin (25 ~tl, 10 U/ml) for an 
additional 15 minutes: porcine intestinal mucosa 
heparin (Solopak Laboratories, Elk Grove, Ill.), bo- 
vine lung heparin (Upjohn Company, Kalamazoo, 
Mich.), and low molecular weight heparin (enoxapa- 
fin) (Lovenox, Rhone-poulenc Rorer Pharmaceuti- 
cals, Inc., Collegeville, Pa.). Platelet aggregation was 
measured using a dual channel aggregometer 
(Chrono-log Corporation, Havertown, Pa.). 
An aggregometer transmits light through sus- 
pended platelets. As aggregation occurs, the optical 
density (OD) of the column of plasma decreases and 
is associated with an increased percent light transmit- 
tance. Although any deflection of the OD curve 
indicates that some platelet aggregation is occuring, 
a more accepted indication for aggregation is a 
greater than 20% change in OD. Aggregation param- 
eters measured included the slope of the aggregation 
curve, maximum percent change in OD, and lag time 
until the start of aggregation. If aggregation did not 
occur, 25 pA of adenosine diphosphate (ADP) (10 -s 
mol/L solution) was added to assess whether ADP- 
associated platelet aggregation was also inhibited by the 
c7E3 Fab fragment. 
The proportion of HAAb-positive plasmas that 
demonstrated platelet aggregation i  the presence of 
saline solution was compared with e proportion in 
the presence of c7E3. A positive result of an aggre- 
gation study was defined in two ways. The first defi- 
nition was any upward deflection in the aggregation 
curve; the second efinition was a greater than 20% 
change in optical density. The results were compared 
using a McNemar's test, considering a two-sided 
alternative. Significant results are those with a p value 
less than 0.01. 
An enzyme-linked immunosorbant assay 
(ELISA) was developed to assess whether the c7E3 
Fab fragment interferes with the binding of heparin 
to the heparin-associated antibodies. Microtiter 
plates were coated with porcine heparin (1 Unit). 
Nonspecific binding sites on the microtiter plates 
were blocked with 3% bovine salt albumin (BSA) in 
phosphate-buffered saline solution (PBS). Platelet- 
poor pooled plasma from 40 patients with HAAb 
(100 bd) was incubated in the microtiter wells (n = 
5) with either PBS or 30 b~g/ml c7E3 Fab fragment. 
A second set of five incubations were performed in 
separate wells with normal platelet-poor plasma (100 
~1). Goat antihuman-IgG (100 ~1, 1:500 concentra- 
tion) (Sigma Chemical Co., St. Louis), conjugated 
with alkaline phosphatase, was added to all wells. To 
detect he presence of heparin-associated antibody 
and antihuman-IgG, p-nitrophenyl phosphate (1 
mg/ml) (Sigma Chemical Co.) was added as a color- 
imetric substrate for the alkaline phosphatase. The 
reaction was stopped after 60 minutes with 2 N 
NaOH, and the plates were read at 405 nm wave- 
length with a microplate reader (Anthos HTII, An- 
thos Labtec Instruments, Salzburg, Austria). 
The ELISA, when performed using undiluted 
plasma, resulted in spectrophotometric absorbances 
outside of the practical range. More usable measure- 
ments were obtained when the HAAb-positive and 
HAAb-negative plasmas were serial diluted, with a 
range from 1:8 to 1:1024. This resulted in dilution 
curves, expressed as OD, which were characteristic 
for each plasma sample and for each incubation with 
either c7E3 or PBS. The OD from incubations con- 
taining PBS were compared with the OD from c7E3 
incubations. In addition, the OD from the ELISA 
performed with HAAb-positive plasma was com- 
pared with the OD from HAAb-negative plasma. 
The dilution curves were fit to a quadratic equation, 
and a multivariate A_NOVA was used for the statisti- 
cal analysis. Significant results are those with a p value 
less than 0.01. In addition, 95% confidence intervals 
were determined when comparisons were made be- 
tween various incubation curves. 
RESULTS 
The aggregation results were expressed as the 
average _+ standard eviation of the 21 patient sam- 
ples. If positive aggregation is defined as any upward 
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Fig. 1. Dilution versus optical density for HAAb-positive 
and HAAb-negative plasmas incubated either with c7E3 or 
phosphate buffered saline (PBS). 
deflection in the OD curve, platelet aggregation oc- 
cured in 100%, 100%, and 95% of the plasma-saline 
incubations exposed to porcine heparin, bovine h p- 
arin, and enoxaparin, respectively. Normal donor 
platelets aggregated in 20 out of 21 plasma samples 
containing HAAb when they were exposed to enox- 
aparin. The one HAAb plasma-saline incubation that 
did not aggregate with enoxaparin demonstrated 
strong platelet aggregation when 10 -s mol /L  ADP 
was added. 
If positive aggregation is defined as a greater than 
20% change in OD, platelet aggregation occured in 
100%, 100%, and 71% of plasma-saline incubations 
exposed to porcine heparin, bovine heparin, and 
enoxaparin, respectively. All HAAb-positive plasma- 
saline incubations demonstrated a greater than 20% 
change in OD when exposed to bovine and porcine 
heparin. Six of the 21 HAAb-positive plasmas had a 
less than 21% change in OD when exposed to enox- 
aparin. This group of six includes the one HAAb 
plasma-saline incubation that had no upward deflec- 
tion in the aggregation curve whatsoever. 
Complete (100%) inhibition of platelet aggrega- 
tion occurred when donor platelets were incubated 
with the c7E3 Fab fragment. This was true for por- 
cine heparin, bovine heparin, andenoxaparin. When 
10- 5 mo l /L  ADP was subsequently added, aggrega- 
tion occured in none of the 21 plasma test samples. 
The proportion of HAAb-positive plasmas that ex- 
hibited aggregation i the presence of saline solution 
versus c7E3 Fab fragment was significantly different. 
The data and p values are summarized in Table 1. 
The OD results for the ELISA assays are pre- 
sented in Table II and are expressed as the average -+ 
standard eviation. Fig. 1 is a graphical presentation 
Table I. Proportion of HAAb-positive 
plasmas with positive aggregation 
Porcineh~a~n Bovineh~aHn Enoxapa~n 
Salme* 21/21 21/21 20/21' 
c7E3 Fab* 0/21 t 0/21~ 0/21~ 
Salines 21/21 21/21 15/21 
c7E3 Fab$ 0/21 t 0/21 t 0/21§ 
*Definition of (+) aggregation is an upward eflection i optical 
density. 
"~Significant difference b tween saline solution and c7E3 Fab (p < 
0.0001). 
SDefirdtion of (+) aggregation s >20% change inoptical density. 
§Significant difference b tween saline and c7E3 (p < 0.0005). 
of the OD for HAAb-positive and HAAb-negative 
plasmas incubated either with c7E3 or phosphate 
buffer. The HAAb-positive plasma ELISA with phos- 
phate buffer alone (n = 5) was compared with the 
ELISA assays incubated with c7E3 (n = 5). The 
incubation with c7E3 was not significantly different 
from the incubation with PBS (p = 0.225). How- 
ever, the ELISA with HAAb-positive plasma was 
significantly different han the ELISA with HAAb- 
negative plasma using a multivariate analysis of vari- 
ance (p = 0.0001). 
Ninety-five percent confidence intervals (CI) 
were determined for the difference in OD between 
incubations with c7E3 and PBS. The 95% CI were 
narrow, ranging from -0.099 to +0.034 at the 1:8 
dilution, to -0.088 to +0.045 at the 1:1024 dilu- 
tion. These narrow intervals suggests that c7E3 
caused no significant interference in the binding of 
HAAb by heparin. 
Ninety-five percent CI also were determined for 
the difference between ELISA dilution curves with 
HAAb-negative pooled plasma and HAAb-positive 
pooled plasma. The 95% CI demonstrated the great- 
est difference at the 1:8 dilution (+0.547 to 
+0.651), and the least difference at the 1:1024 dilu- 
tion (-0.013 to +0.091). At dilutions of 1:128 or 
less, the 95% CI indicates a clear separation with a 
difference in OD of at least 0.1 (Fig. 1). 
DISCUSSION 
Platelet function inhibiting agents have been 
used with variable success in the management of 
HAAb-positive patients who need continued antico- 
agulation with heparin. Included among these agents 
have been aspirin, dipyridamole, and iloprost (a pros- 
tacyclin analog). 5-7 Aspirin, an inhibitor of cyclooxy- 
genase and thromboxane A2 production, does not 
reliably inhibit platelet aggregation i  all patients. 
Although iloprost may increase the protection 
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Table II. ELISA, optical density at various dilutions 
Dilution 8 16 32 64 128 256 512 1024 
HAAb (+)  1,091 ± 0.03 0.945 +- 0.11 0.699 ± 0.06 0.541 ± 0.06 0.393 ± 0.05 0.256 ± 0.03 
buffer 
HAAb (+)* 1,093 +_ 0.17 0.900 ± 0.09 0.680 ± 0.02 0.485 ± 0.04 0.346 ± 0.03 0,228 ± 0.02 
c7E3 
HAAb (-)-~ 0.562 ± 0.01 0.462 --_ 0.02 0.326 +_ 0.03 0.263 _+ 0.04 0.210 ± 0.01 0.142 ± 0.02 
buffer 
HAAb ( - )  0.460 ± 0.04 0.386 ± 0.03 0.344 ± 0.03 0.234 ± 0.06 0.188 ± 0.03 0.116 ± 0.01 
c7E3 
0.187 ± 0.01 0.123 ± 0,01 
0.146 ± 0.01 0.098 ± 0,01 
0.088 ± 0.010,077 ± 0.01 
0.084 ± 0.02 0.066 _+ 0.01 
*In HAAb (+) plasma, c7E3 caused no significant change in the optical density curve when compared with buffer alone using ANOVA 
(p = 0.225). 
tOptical density with HAAb (+) plasma was significantly greater than the optical density with HAAb ( - )  plasma using ANOVA (p = 
0.0001). 
HAAb-positive patients during reexposure to hepa- 
fin, it causes significant hypotension i  some pa- 
tients 8,9 and is not recommended at present. 
Alternative anticoagulants (low molecular weight 
heparins and heparinoids, ancrod, and hirudin) have 
been used in patients with HIT)  °-is Low molecular 
weight heparins and heparinoids may be used if the 
platelet aggregation assays demonstrate no cross-re- 
activity with heparin. 14-16 However, cross-reactivity 
rates vary from 20% to 88%. This variable cross- 
reactivity explains why enoxaparin did not cause 
platelet aggregation i  up to five of 21 (29%) HAAb- 
positive patients. 
Ancrod is a defibrinogenating agent hat has been 
used as an alternative anticoagulant in HAAb-posi- 
tive patients with deep vein thromboses. It also has 
been used successfully as a perioperative anticoagu- 
lant in patients undergoing cardiovascular proce- 
dures) 2,17 Hirudin, a direct inactivator of thrombin, 
is another alternative toheparin that has been used in
a small number of HAAb-positive patients? 3 At 
present, neither ancrod nor hirudin is approved by 
the Food and Drug Administration for clinical use. 
In addition, potential problems with ancrod include 
the development of antibodies and resistance to an- 
ticoagulation. 15 
A monoclonal ntibody against the glycoprotein 
I Ib/I I Ia receptor was developed by Coller et al. in 
198378 Platelet aggregation i response to ADP, 
epinephrine, and thrombin was inhibited in a dose- 
dependent fashion, c7E3 is the Fab fragment (vari- 
able region) of an IgG antibody produced via mam- 
malian cell culture, and is directed against the platelet 
GP I Ib/I I Ia receptor. The constant region of the 
intact antibody has been removed, via the restriction 
enzyme papain to decrease the antigenicity of the 
molecule. 
After intravenous bolus administration, free c7E3 
has an initial half-life of 10 minutes and a second- 
phase half-life of 30 minutes. This 10 minute half-life 
is most likely a result of rapid binding to the platelet 
GP IIb/IIIa receptor. Platelet fimction recovers within 
approximately 48 hours after a bolus but can be inhib- 
ited for longer periods with a continuous infusion of 
c7E3. Greater than 80% GP IIb/IIIa receptor blockade 
is achieved in vivo when c7E3 is administered with an 
intravenous bolus dose of 0.25 mg/kg followed by a 
continuous infusion of 10 txg/min. 
More recently, monoclonal GP I Ib/I I Ia anti- 
bodies have been used totreat patients after coronary 
angioplasty and thrombolysis to reduce the risk for 
reocclusion, and to treat patients with unstable angi- 
na. 19-21 These studies demonstrated a ecreased risk 
of ischemic omplications in all groups. The largest 
of these studies also demonstrated a significantly in- 
creased risk of bleeding complications in patients 
who received ac7E3 bolus and infusion, when com- 
pared with placebo (14% vs 7%). 19 Allergic or hyper- 
sensitive reactions are extremely rare. Hypotension, 
nausea, vomiting, bradycardia, nd fever have been 
recorded in few patients. 
This report demonstrates that the GP IIb/IIIa, 
c7E3 Fab fragment, effectively inhibits in vitro plate- 
let aggregation when HAAb-positive plasma is incu- 
bated with bovine, porcine, and the low molecular 
weight heparin, enoxaparin. It has been demon- 
strated that the monoclonal antibody binds to the 
GP I Ib/I I Ia platelet receptor and blocks the binding 
to platelets of fibrinogen and other glycoproteins 
(fibronectin, von Willebrand factor, and vitronec- 
tin)) 8,22 The c7E3 Fab fragment may be the stron- 
gest platelet function-inhibiting a ent available for 
use in HAAb-positive patients who require contin- 
ued heparin anticoagulation for acute thrombotic 
disorders or cardiovascular operations. We per- 
formed ELISAs to evaluate whether c7E3 also inter- 
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fered with the binding of heparin to HAAb. The 
ELISAs indicated that c7E3 does not interfere with 
the binding between heparin and HAAb. It is possi- 
ble that the number of assays (five in each group) 
were too few to identify differences in the binding of 
heparin and HAAb. Additional studies are underway 
to determine whether a small difference exists. Nev- 
ertheless, any interference caused by c7E3 in the 
binding between heparin and HAAb appears to be 
small. The major mechanism by which c7E3 prevents 
platelet aggregation appears to be the inhibition of 
binding offibrinogen and other glycoproteins to the 
GP IIb/IIIa receptor. 
Although this study used donor platelets to de- 
tect the presence or absence of aggregation, it is 
likely that c7E3 also would inhibit aggregation when 
platelets from HAAb-positivc patients are tested. Re- 
gardless of the platelet source and the agonist caus- 
ing activation, c7E3 blocks the final common path- 
way of platelet aggregation, the binding of 
fibrinogen and fibrin to the platelet GP IIb/IIIa 
receptor. Assays to detect platelet activation (e.g., 14 
C serotonin release) were not performed because 
there was little reason to doubt that platelet activa- 
tion had occurred. The saline control platelet aggre- 
gation assays clearly demonstrated the presence of 
significant activation and aggregation. 
Clinical trials using c7E3 in HAAb-positive pa- 
tients who require continued hcparin-like anticoagu- 
lation (especially vascular surgery, cardiac surgery, 
and vascular radiology patients) are planned. Some 
questions that remain to be answered about c7E3 in 
patients with HIT include: Does c7E3 prevent or 
aggravate thrombocytopenia n vivo in patients with 
HIT? What is the fate of platelets activated but not 
aggregated by the HAAb? What is the adequate dose 
of c7E3 for patients with HIT? Besides the risk of 
bleeding, will there be other complications from the 
use ofc7E3? 
We gratefully acknowledge the assistance of Ri hard 
Madsen, PhD, for his statistical analysis, and Connie Stick- 
ney for her preparation of the manuscript. 
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DISCUSSION 
Dr. William C. Krupski (Denver, Colo.). I would like 
to congratulate Dr. Liem and his colleagues for performing 
an interesting, well-conducted study and for p esenting it
so clearly here today. I would also like to congratulate allof 
you in the audience for sticking around until the bitter end, 
because I think that this is one of the most important 
papers of the entire program. Dr. Silver and his associates 
at the University of Missouri have led the way in the 
recognition, diagnosis, and management ofthe formidable 
problem of heparin-induced or heparin-associated hrom- 
bocytopenia, which is also called HIT or HAT. 
HAAb binds with platelet receptors that initiate intra- 
cellular signaling pathways, which gives rise to conforma- 
tional change in the membrane GP I Ib/ I I Ia,  whereby 
these sites bind avidly with fibrinogen or other bivalent 
adhesive proteins, which in turn leads to platelet-platelet 
interaction that we call aggregation. GP I Ib / I I Ia  is a calci- 
um-dependent heterodimer that belongs to a general class 
of structurally similar adhesion receptors that are desig- 
nated as integrins. These receptors interact with the amino 
acid sequence arg-gly-asp, or RGD, common to several 
proteins that mediate cell adhesion and cohesion. Expres- 
sion of functional fibrinogen r ceptors i the final common 
pathway in the process ofplatelet recruitment. Therefore, 
GP I Ib / I I Ia  is an important target for interventions aimed 
at interrupting clinically significant, pathologic thrombo- 
sis. 
Directly blocking GP I Ib / I I Ia  receptor on platelets is 
an attractive strategy for preventing pathologic thrombo- 
sis. There are three categories of molecules that have been 
evaluated for this purpose. The first category include natu- 
rally occurring RGD-containing proteins, such asechista- 
tin, bitistatin, and applagin, that are isolated from the 
venom of various species of vipers. The second category 
comprises ynthetic peptides with one or more RGD se- 
quences; several are currently under evaluation, but none 
has yet been approved for clinical use. Monoclonal anti- 
bodies that specifically bind and inhibit GP I Ib / I I Ia  make 
up the third category. In a sense, the administration of 
such antibodies creates aphysiologic state that is compara- 
ble with that seen in patients with Glanzmann thrombas- 
thenia who are deficient in membrane GPs IIb and IIIa. 
These patients have prolonged bleeding and an abnormal 
aggregation response. 
The in vitro study reported today demonstrates that 
routine monoclonal antibody, c7E3-a fibrinogen receptor 
antagonist-prevents platelet aggregation induced by 
HAAb without blocking the binding of HAAb to platelets. 
This result is predictable because HAAb binds with the 
Fc-like receptors eparate from membrane GP I Ib/ I I Ia.  
Accordingly, HAAb will bind without interfering with the 
fibrinogen receptor, and vice versa. Because in vitro aggre- 
gation absolutely depends on fibrinogen receptors to me- 
diate platelet aggregation, platelet activation by HAAb will 
induce the xpression of functional fibrinogen receptors, 
but if the fibrinogen receptors are blocked by their binding 
with c7E3, aggregation cannot proceed. 
The potential usefulness of administering c7E3 in vivo 
depends on the relative importance of three unknown 
factors, and my questions to the authors relate to their 
speculation on what might occur. 
The first unknown is the extent o which platelets are 
destroyed by immune-mediated mononuclear phagocytic 
removal that results from the binding of HAAb to platelets, 
similar to other immune-mediated destructive processes. If
this process predominates, c7E3 will have no significant 
protective ffect on the platelet count. 
The second unknown is the extent o which platelets 
are removed because of HAAb-dependent activation of 
platelets. As the authors themselves ask, what is the fate of 
platelets that are activated but not aggregated by c7E3? If 
platelets are removed by the consequent formation of ag- 
gregates/microemboli and microvascular occlusion, c7E3 
will be protective if the microembolic mechanism impairs 
the primary process. 
The third unknown is the extent o which c7E3 im- 
pairs critical hemostasis. It is well established that the dose 
of c7E3 that is needed to protect he platelet count will 
severely interrupt platelet hemostatic function, with bleed- 
ing times greater than 30 minutes. The combination of 
heparin anticoagulation and c7E3-mediated paralysis of 
platelet hemostasis may not be compatible with perform- 
ing cardiac or vascular surgical procedures without unac- 
ceptable risk. The relative importance of each of these 
variables may be quite different in individual patients, thus 
making it impossible to predict the outcome in different 
patients. 
Finally, it will be some time before human clinical trials 
are completed to ascertain the efficacy of c7E3 in patients 
with HIT. In the meantime, what advice would you give us 
when we encounter a patient with this disorder now? 
Dr. Timothy K. Liem (Columbia, Mo.). Regarding 
the question of whether the heparin-activated platelets are 
eliminated by immune-mediated phagocytosis, we have no 
clear answer, but I would speculate that this elimination 
occurs to some extent. There is one difference between the 
heparin thrombocytopenia syndrome and other drug-in- 
duced or immune-mediated processes. In the latter condi- 
tions, the antibody is directed against he platelet, thereby 
exposing the Fc portion for efficient opsonization. In hep- 
arin thrombocytopenia, the antibody is directed against 
heparin, possibly in combination with platelet factor 4. The 
Fc portion of the antibody attaches to the platelet Fc 
receptor that causes platelet activation. 
This leads to the second and related question of 
whether the thrombocytopenia is caused by the formation 
of platelet aggregates. There is some evidence that this 
occurs. A few studies have evaluated thrombi removed 
from patients with the heparin thrombocytopenia syn- 
drome. These are often white and rich with platelets, so 
called "white clot." 
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Use of c7E3 is associated with an increased incidence 
of bleeding in patients who undergo percutaneous coro- 
nary angioplasty in phase 3 trials. The risk of bleeding 
during cardiac and vascular procedures i most likely in- 
creased as well when concomitant c7E3 is given. 
Our current approach to patients with hepatin throm- 
bocytopenia ncludes, first and foremost, discontinuation 
of the heparin. If  the patient requires further anticoagula- 
tion therapy, low molecular weight heparins are used if 
platelet aggregation studies demonstrate no cross-reactiv- 
ity with the unfractionated heparin. Long-term anticoagu- 
lation with warfarin is started as well. If  the low molecular 
weight heparin does cross-react, our next choice for anti- 
coagulation therapy would be ancrod possibly obtained 
through a compassionate use protocol. 
Dr. Jawed Fareed (Maywood, Ill.). I would like to 
make three comments on your presentation. 
The first is that these results you presented with the 
antibodies are consistent with what we presented in Febru- 
ary at a Society meeting. Not only the antibodies, the 
ReoPro, or c7E3 antibody ou described, but also a chi- 
meric antibody from Japan, YM337, and the synthetic 
inhibitors, which were described by our discussant, pro- 
duced the blunting of the heparin-induced thrombocyto- 
penia. 
There are synthetic agents that are currently being 
developed for oral usage that are much more active in 
subnanogram amount in blunting this effect. So the con- 
cern that is expressed by our discussant that the primary 
hemostatic function that may be blunted by the c7E3 
could be answered that we could use these newer agents, 
the synthetic inhibitors, at a very low concentration will 
not affect he primary hemostasis and they are readily more 
reversible than the antibody. 
The second comment is the agent you described, hiru- 
din, and some of the other antithrombin agents, are in 
clinical trial at the present time for heparin-induced throm- 
bocytopenia both in Europe and in the United States. I
wish to ask you whether you tried hirudin or some of the 
antithrombin agents in your studies or in the in vitro 
testing of these agents? 
I do not completely agree with the conclusion you 
have on the comparison of heparin and low molecular 
weight heparins. I am also not clear on what concentration 
you used for the low molecular weight heparin. If  you 
increase the concentration of these agents, low molecular 
weight heparin also produces a similar degree of heparin- 
induced thrombocytopenic effect in vitro as well as in vivo. 
So when we use this low molecular weight heparin at the 
very high concentration or dosage, there is no practical 
difference; however, there is a synthetic pentasaccharide, 
which has recently been developed and will go in clinical 
trial in this country, that is devoid of the heparin-induced 
thrombocytopenic potential, at least in vitro conditions. So
I am pleased that this forum included this very important 
paper, which has practical implications, and your findings 
are very clear. I hope we can provide the GP I Ib / I I Ia  
inhibitors that can be safe in addition to producing the 
platelet inhibition that could also be given simultaneously 
with heparin. 
So the final question I wish to ask is whether you have 
used any of the hirudin or thrombin inhibitors, such as 
argatroban and some of the newer synthetic inhibitors, in 
your assay for the effects you have observed with the GP 
I Ib / I I Ia  antibody. 
Dr. Liem. First, regarding the "hemostatic effects" of 
c7E3. In the largest clinical trial, patients received a bolus 
injection followed by an infusion of c7E3. These patients 
did have prolonged bleeding times greater than 30 min- 
utes. After about 48 hours the bleeding time decreased to 
less than 12 minutes. 
I am unfamiliar With clinical trials that are using the 
synthetic GP I Ib / I I Ia  inhibitors in heparin thrombocyto- 
penia patients. 
We have not used hirudin or argatroban or any of the 
numerous other direct thrombin inhibitors in HIT pa- 
tients, but we would look forward to using those agents in 
the future. 
We have used low molecular weight heparin in three or 
four patients with heparin thrombocytopenia who had no 
cross-reactivity with unfractionated heparin. We found that 
low molecular weight heparin can be used successfully with 
prevention of the thrombotic processes. 
Dr. G. Patrick Clagett (Dallas, Tex.). I am very 
curious as to what specific type of patient and what clinical 
scenario you are going to treat with this drug. Short-term 
use, as during a vascular operation, might be disastrous 
because of the bleeding complications. And it seems to me, 
i f I  recall correctly, that the antibody itself is immunogenic 
and so a more prolonged use would have limited effective- 
ness. So I 'm trying to think of a patient in whom you're 
going to use this, and I am not sure exactly what that 
would be. I 'd like your comments. 
Dr. Liem. We would first try c7E3 in patients with 
deep vein thromboses who require further anticoagulation 
therapy. It could be given in the interim period until the 
warfarin is adequately effective as an antithrombotic agent. 
Regarding the question about whether it causes anti- 
genicity, so far the clinical trials have used bolus injections 
with less than 72 hours of infusion, and we would hope 
that in that period of time the rate of developing allergic 
reactions, or antigenicity, would be quite low. 
